If you have been reading about As-needed dosing and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
CO(NH2)2 + HNCO → NH2CONHCONH2 NH2CONHCONH2 + HNCO → NH2CONHCONHCONH2 At higher temperatures it converts to a range of condensation products, including cyanuric acid (CNOH)3, guanidine HNC(NH2)2, and melamine.
=== Diseases and conditions === Infectious diseases which increase nutrient requirements, such as gastroenteritis, pneumonia, malaria, and measles, can cause malnutrition. So can some chronic illnesses, especially HIV/AIDS. Malnutrition can also result from abnormal nutrient loss due to diarrhea or chronic small bowel illnesses, like Crohn's disease or untreated coeliac disease. "Secondary malnutrition" can result from increased energy expenditure. In infants, a lack of breastfeeding may contribute to undernourishment. Anorexia nervosa and bariatric surgery can also cause malnutrition.
Aside from the conquest of England and the subsequent invasions of Wales and Ireland, the Normans expanded into other areas. Norman families, such as that of Tancred of Hauteville, Rainulf Drengot and Guimond de Moulins played important parts in the conquest of southern Italy and the Crusades. The Drengot lineage, de Hauteville's sons William Iron Arm, Drogo, and Humphrey, Robert Guiscard and Roger the Great Count progressively claimed territories in southern Italy until founding the Kingdom of Sicily in 1130. They also carved out a place for themselves and their descendants in the Crusader states of Asia Minor and the Holy Land.
Sources: en.wikipedia.org
=== Apodization in imaging === Since side lobes of the Airy disk are responsible for degrading the image, techniques for suppressing them are used. If the imaging beam has a Gaussian distribution, then when the truncation ratio (the ratio of the diameter of the Gaussian beam to the diameter of the truncating aperture) is set to 1, the side-lobes become negligible and the beam profile becomes purely Gaussian. In medical ultrasonography, the effect of grating lobes can be reduced by activating ultrasonic transducer elements using variable voltages in the apodization process.
== Operations == UPS's primary business is the time-definite delivery of packages and documents worldwide. In recent years, UPS has extended its service portfolio to include less-than-truckload (LTL) transportation and supply chain services, primarily in the U.S. UPS reports its operations in three segments:
=== Cellulose nanocrystals === Cellulose nanocrystals (CNCs), or nanocrystalline cellulose (NCC), are highly crystalline, rod-like nanoparticles. They are usually covered by negatively charged groups that render them colloidally stable in water. They are typically shorter than CNFs, with a typical length of 100 to 1000 nanometers.
Various work-related elements impact overall well-being, such as the character of the work performed, income, job security, work-life balance, and personal relationships to coworkers and superiors. Job loss and unemployment are associated with a decrease in well-being because of factors such as financial strain caused by lost wages, weakened social connections, and a reduced sense of purpose and social status. The government and political situation, another determinant, influences the happiness of the population by affecting security, equality, social services, and a general trust in society. Accordingly, governments that uphold the rule of law, provide good services, and control corruption tend to foster higher levels of well-being. Opportunities to democratically participate in political decision-making are also linked to increased well-being. Similarly, the physical environment plays a role, with factors like housing conditions, pollution, noise, and access to nature and recreational areas. The genetic makeup can significantly impact the general level of a person's well-being, with some studies suggesting that genetic influences can explain up to one third of the differences in subjective well-being. For example, the life satisfaction of identical twins, who share genes, is more alike than the life satisfaction of non-identical twins. Other relevant biological factors include neurotransmitters and hormones.
Sources: en.wikipedia.org
The reduction of the permissible exposure limit (PEL) for respirable crystalline silica from 250 to 50 micrograms per cubic meter of air, averaged over an 8-hour shift. Shifts the focus of controlling silica exposure from the use of PPE (respirators) to the use of engineering controls (such as using water-integrated tools or vacuum systems) and administrative controls (limiting exposure time per shift). Employers are still required to provide respirators when engineering and administrative controls cannot adequately limit exposure. Additional provisions include limiting worker access to high exposure areas, signage requirements in high exposure areas, the development of a written exposure control plan, and training for workers on silica risks and how to limit exposures. Special equipment may be needed to prevent machine water from evaporating and leaving behind dust, and the standard also provides requirements for cleaning up the slurry left behind when water-integrated tools are used as an engineering control. Requires medical exams for highly exposed workers which include a discussion with a physician or licensed health care provider (PLHCP) of prior respiratory health, chest X-ray, pulmonary function test, latent tuberculosis infection, and any other tests deemed necessary by the PLHCP, which are to occur within 30 days of initial silica exposure and must be made available for renewal at least every three years unless the PLHCP deems otherwise.
=== Religion and schools === In 2019, Schmitt spoke in defense of the Cameron R-1 School District after it came under criticism from the Freedom From Religion Foundation over a high school football coach who led students in prayer before and after games. The group contended that the practice violating the Establishment Clause of the First Amendment. In a letter, Schmitt called the foundation an "extreme anti-religion organization" and said he would support the coach, school, and school district if the group sued.
The e-cigarette vapor is generated when the e-liquid is vaporized by the heating element or by other mechanical methods. The last step of vapor processing happens as the e-cigarette vapor passes through the main air passage to the user. For some advanced devices, before inhaling, the user can adjust the heating element temperature, air flow rate or other features. The liquid within the chamber of an e-cigarette is heated to roughly 100-250 °C to create an aerosolized vapor. This is thought to result in pyrolysis of the e-liquid and could also lead to decomposition of other liquid ingredients. The aerosol (mist) produced by an e-cigarette is commonly but inaccurately called vapor. In physics, a vapor is a substance in the gas phase whereas an aerosol is a suspension of tiny particles of liquid, solid or both within a gas. The power output of the e-cigarette is correlated to the voltage and resistance (P = V2/R, in watts), which is one aspect that impacts the production and the amount of toxicants of e-cigarette vapors. The power generated by the heating coil is not based solely on the voltage because it also relies upon the current, and the resultant temperature of the e-liquid relies upon the power output of the heating element. The production of vapor also relies upon the boiling point of the solvent. Propylene glycol boils at 188 °C, while glycerin boils at 290 °C. The higher temperature reached by glycerin may impact the toxicants emitted by the e-cigarette. The boiling point for nicotine is 247 °C.
electrophoresis The physical separation of molecules, e.g. nucleic acids or proteins, according to their movement through a fluid medium to which an electric field is applied, where the distance they travel is proportional to their size. Because of their negatively charged phosphate backbones, nucleic acids are repelled by the negative electrode at one end of the medium and attracted to the positive electrode at the other end, which causes them to be pulled toward the latter over time; denatured proteins and even whole cells may migrate through the medium in a similar manner. The speed at which the molecules migrate depends on their net electric charge and is inversely proportional to their overall size (i.e. the number of atoms they contain), such that very small molecules tend to move faster through the medium than very large molecules. Thus electrophoretic techniques, particularly gel electrophoresis with agarose or polyacrylamide-based gels as the supporting medium, are widely used in molecular biology laboratories to quickly and conveniently isolate molecules of interest from heterogeneous mixtures and/or identify them based on their expected molecular weight. Reference markers containing molecules of known weight are commonly run alongside unknown samples to aid size-based identification. Electrophoresis is often combined with other techniques such as immunolabelling and radiolabelling.
in PAMn is equal to the number of mutated amino acids per 100 amino acids. To find the mutation matrix for the PAM1 matrix, the requirement that 99% of the amino acids in a sequence are conserved is imposed. The quantity
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.